CLU and coronary artery disorder: Conversely, the combined statin/niacin therapy increases levels of clusterin/apoJ in the HDL3 subpopulation of CAD patients, reverting the lipoprotein profile to the one more closely resembling that of HDL3 in healthy control subjects43.